Create more data on roflumilast efficacy, says NICE
Clinical trials need to be set up to establish how effective roflumilast is before the drug can be recommended for NHS use, the National Institute for Health and Clinical Excellence has said.
In final guidance published today (25 January 2012), NICE’s independent technology appraisal committee concluded that the NHS would benefit from having robust trial data on the clinical and cost effectiveness of roflumilast (Daxas; Merck, Sharp & Dohme).
In other guidance, NICE recommended apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) for use on the NHS in England and Wales.
It also endorsed the use of rituximab (MabThera, Roche), in combination with a range of chemotherapy regimens, for the first-line treatment of advanced follicular lymphoma. The drug is recommended for use in combination with: cyclophosphamide, vincristine and prednisolone; mitoxantrone, chlorambucil and prednisolone; cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon alfa; or chlorambucil.
Evidence shows that the addition of rituximab helps patients to live longer and improves quality of life, compared with chemotherapy alone, NICE says.
Citation: The Pharmaceutical Journal URI: 11093677
Recommended from Pharmaceutical Press